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Aim: The aim of this study is to investigate relation between severity of the disease
and heart rate variability, diastolic dysfunction and arrhythmia in patients with
psoriasis vulgaris.
Patients and Method: Fifty- three psoriasis patients (28 F, 25 M), 30 healthy
volunteer were enrolled in the study. Severity of the psoriasis disease was evaluated
by Psoriasis Area and Severity Index (PASI) score. The patients who have PASI score
10 were groupped as mild psoriasis and the patients who have PASI score >10 were
groupped as severe psoriasis. Patients with hypertension, diabetes mellitus, thyroid
disease, chronic liver disease, chronic renal failure, valvular heart disease, congestive
heart failure, coronary artery disease, cerebrovascular event history and patients who
have history of medical treatment which can lead to arrhythmia were excluded. BUN,
creatinine, AST, ALT, fT3, fT4, TSH, fasting blood glucose, total cholesterol, try-
gliseride, HDL cholesterol, LDL cholesterol, TNF-a and Hs-CRP were tested in all
patients. All patients were evaluated with transthorasic echocardiography. Twenty-
four-hour ambulatory electrocardiogram holter monitoring was performed.
Results: Diastolic blood pressure measurements of patients with psoriasis were
signiﬁcantly higher than control group (p:0.001). HDL cholesterol values in both mild
and severe psoriasis groups were signiﬁcantly lower than the control group (p<0.05).
Hs-CRP level in severe psoriasis group was signiﬁcantly higher than the other groups
(p:0.001). Left ventricular end diastolic diameter, end systolic diameter, LVEF, septum
and posteriorwall thickness’, left atrium diameter measurements were similar among the
groups.Mean standard deviation of mean of normal-to-normalin intervals (SDANN)
which one of the parameters of the heart rate variability was in mild psoriasis group
130.139.2 msec, in severe psoriasis group 118.439.9 msec and in control group
126.739.3 msec (p:0.012). Frequency of supraventricular ectopy and ventricular
ectopy are similar among the groups. Serious conduction defects, supraventricular
tachycardia and ventricular tachycardia were not determined in 24-h holter monitoring.
Conclusıon: HDL cholesterol level in patients with psoriasis was lower than control
group.Mean SDANNmean, mean and night percentage of R-R intervals with more than
50 msec variation (PNN50), mean and night root mean square of differences between
adjacent normal-normal intervals (RMSSD)which one of the parameters of the heart rate
variability were lower in severe psoriasis group. As previous studies showed, reduced
heart rate variability is a risk factor for cardiovascular morbidity and total mortality.
Increased cardiovascular risk may be related with those ﬁndings in patient with psor-
iasis.In this study, our data suggests possible explanation for high incidence of cardio-
vascular disease in psoriasis patients and need to further prospective clinical trials.
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Background: Plasminogen activator inhibitor type 1 (PAI-1) regulates ﬁbrinolysis,
and the common promoter region variants -675G/A (4G/5G) is associated with
increased thrombotic risk. High levels of PAI-1 have been implicated as a risk factor
for cardiovascular disease. The 4G allele is associated with higher levels of PAI-1, and
might increase the risk for intravascular thrombosis. Atrial ﬁbrillation (AF) renders
individual patients at risk for development of an atrial thrombus. AF increases the risk
of stroke by 4-5-fold, particularly in the elderly. Several pathophysiological mecha-
nisms of the left atrial thrombogenesis have been suggested. Therefore, genetic
variations affecting expression levels and activity of haemostatic factors could
presumably modulate the risk of thrombogenesis in AF. We investigated the PAI-1
4G/5G (-675G/A) polymorphisms in nonvalvular AF with Ischemic Stroke.
Methods: The PAI-1 4G/5G polymorphisms were analysed in 70 patients with
nonvalvuler AF who have had a stroke and 70 healthy individuals with no docu-
mented episode of AF matched for age, race and sex. The PAI-1 4G/5G poly-
morphisms were identiﬁed by polymerase chain reaction (PCR) method. DistributionC122 JACC Voof the PAI-1 4G/5G polymorphism genotypes (Normal (5G/5G) genotype, hetero-
zygous mutant genotype (4G/5G) or homozygous (4G/4G) mutant genotype) were
determined in study population. Demographic characteristics and risk factors for AF
and stroke were evaluated in the study groups.
Results: There was no signiﬁcant difference with respect to age and gender between
groups. There was no statistical difference in genotype distribution among the groups.
The genotype distribution in nonvalvuler AF who have had a stroke group was as
follows: 5G/5G genotype frequency was 29 (41.4%), 5G/4G genotype frequency was
27 (38.6%) and 4G/4G genotype was 14 (20%). The genotype distribution in control
group was as follows: 5G/5G genotype frequency was 37 (52.9%), 4G/5G genotype
frequency was 23 (32.9%) and 4G/4G genotype frequency was 10 (14.3%). There was
no statistically signiﬁcant difference between groups in genotype distributions.
Conclusıons: Our results suggest that the 4G/5G polymorphism of the PAI-1 gene
appears not to be associated with nonvalvular AF with ischemic stroke in Turkish
population.
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Acute or subacute bacterial endocarditis should be suspected in any patient with
a pacemaker manifesting a persistent febrile illness. Embolic complications of IE can
occur as vasculitis, and vasculitis is also a serious complication that develops in
a minority of patients with longstanding, severe, seropositive, erosive, and nodular
rheumatoid arthritis (RA).
A 68-year-old woman with fever, asthenia, night sweats, arthralgia, weight loss, and
necrotizing skin ulcers on the body and lower extremities (Figure 1a) was admitted to
our clinic. She had been followed for RA for over 20 years. The laboratory ﬁndings
revealed granulocytosis, anaemia of chronic infection, high levels of CRP, and sedi-
mentation rate, and low levels of C4. The rheumatoid factor (RF) was 929 IU/ml
(N<10), and anti-cyclic citrullinated peptide (antiCCP) was 56.5 U/ ml (N< 5) at
admission. A month ago, a temporary pacemaker was applied to the patient due to
drug-induced bradyarrhytmia, but the pacemaker's lead fractured and remained inside
the right ventricle while it was removed. The two major criteria for the diagnosis of IE
was conﬁrmed by revealing vegetations on the fractured lead and the tricuspid valve
by echocardiography (Figure 2a-b), and methicillin- resistant coagulase-negative
Staphylococcus aureus in two of the four blood cultures drawn >12 h apart. Van-
comycin and imipenem were commenced for the treatment of IE. The biopsy spec-
imen from the skin ulcers revealed leucocytoclastic vasculitis (LCV) (Figure 3a). In
cases with IE and LCV, a trend to low serum complement levels was evident.This was
associated to an immune complex-mediated process initiated by antigen products of
the infectious agent responsible for the IE, or to the result of abnormal immunoreg-
ulation related to the infectious disease.
Vasculitis is a serious complication of RA that develops in a minority of patients
with this disease, and it is not uncommon in patients with IE. The diagnosis of
rheumatoid vasculitis (RV) was conﬁrmed by the history, clinical and laboratory
ﬁndings of our patient. Methylprednisolon 500 mg intravenous bolus followed by
40mg peroral daily was administered. In spite of all taken measures the patient died of
severe sepsis on the 50th day of her admission.
Rheumatoid vasculitis usually develops in people with at least 10 years of severe
disease when the inﬂammatory arthritis is ‘burned out. High titers of RF are reported
to be the strongest predictor of the development of RV and antiCCP antibodies may be
helpful in distinguishing RV from other forms of small vessel vasculitis. Numerous
medications used to treat RA have also been proposed as triggers of RV, partly
because of some similarities between drug-induced hypersensitivity vasculitis and RV.
In particular, the treatment of RA with oral glucocorticoids has been implicated in the
development of RV. Our patient had been RA for over 20 years and on corticosteroid
therapy of differrent dose regimens since then.l 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTERS
